Skip to content

Study · Ex vivo tissue · chicken · 2003

7 results

The actin binding site on thymosin beta4 promotes angiogenesis.

Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK

FASEB journal : official publication of the Federation of American Societies for Experimental Biology18 Sept 2003Cited by 98 (Europe PMC)

PMID14500546 (opens in a new tab)DOI10.1096/fj.03-0121fje (opens in a new tab)PepBankPUB-14500546
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In chick aortic arch vessel sprouting assays, thymosin beta‑4 was active at about 50 nM.

    In plain wordsIn lab tests with chick aorta tissue, thymosin beta‑4 caused vessel sprouting at about 50 nM.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseVessel sprouting from chick aortic arches
    Study

    chickenn: not reported in source

    Chick aortic arch vessel sprouting assay
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    ~50 nMAs given in this study (chicken).

    Measurements

    Active concentration
    ≈ 50 nM
    aortic arch sprouting

    Source sentences

    Summary
    Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta4 and the actin-binding motif of the peptide display near-identical activity at ~50 nM, whereas peptides lacking any portion of the actin motif were inactive.
  2. 02LabEx vivo tissueMechanism

    Soluble actin at 5-50 nM inhibited the sprouting activity of thymosin beta‑4 in chick aortic arch assays.

    In plain wordsIn lab tests with chick aorta tissue, adding soluble actin at 5-50 nM reduced the vessel sprouting activity of thymosin beta‑4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableSprouting activity of thymosin beta-4 with soluble actin
    Study

    chickenn: not reported in source

    Chick aortic arch vessel sprouting assay
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Soluble actin concentration
    5 to 50 nM
    sprouting inhibition

    Source sentences

    Summary
    The adhesion and sprouting activity of thymosin beta4 was inhibited with the addition of 5-50 nM soluble actin.
  3. 03LabIn vitro (cells)Activity measurement

    In HUVEC migration assays, thymosin beta‑4 was active at about 50 nM.

    In plain wordsIn lab tests with human vein cells, thymosin beta‑4 made the cells migrate at about 50 nM.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHUVEC migration
    Study

    humann: not reported in source

    Human umbilical vein endothelial cells (HUVEC)
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    ~50 nMAs given in this study (human).

    Measurements

    Active concentration
    ≈ 50 nM
    HUVEC migration

    Source sentences

    Summary
    Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta4 and the actin-binding motif of the peptide display near-identical activity at ~50 nM, whereas peptides lacking any portion of the actin motif were inactive.
  4. 04LabIn vitro (cells)Mechanism

    Adhesion to thymosin beta‑4 was blocked by the seven amino acid actin-binding peptide, which identifies it as the major cell binding site of thymosin beta‑4.

    In plain wordsIn lab tests, cell adhesion to thymosin beta‑4 was blocked by a seven amino acid piece of it, the main cell binding site.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableCell adhesion to thymosin beta-4 blocked by the seven amino acid peptide
    Study

    humann: not reported in source

    Endothelial cell adhesion assay
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, adhesion to thymosin beta4 was blocked by this seven amino acid peptide demonstrating it as the major thymosin beta4 cell binding site on the molecule.
  5. 05LabIn vitro (cells)Mechanism

    Soluble actin at 5-50 nM inhibited the adhesion activity of thymosin beta‑4.

    In plain wordsIn lab tests, adding soluble actin at 5-50 nM reduced the cell adhesion activity of thymosin beta‑4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableAdhesion activity of thymosin beta-4 with soluble actin
    Study

    humann: not reported in source

    Endothelial cell adhesion assay
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Soluble actin concentration
    5 to 50 nM
    adhesion inhibition

    Source sentences

    Summary
    The adhesion and sprouting activity of thymosin beta4 was inhibited with the addition of 5-50 nM soluble actin.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    The seven amino acid actin-binding motif of thymosin beta‑4 displayed near-identical migration and sprouting activity to full thymosin beta‑4 at about 50 nM.

    In plain wordsIn lab tests, a seven amino acid piece of thymosin beta‑4 worked almost as well as the whole peptide at about 50 nM.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableActivity of the seven amino acid actin-binding motif versus thymosin beta-4
    Study

    humann: not reported in source

    HUVEC migration and chick aortic arch sprouting assays
    Comparator
    Thymosin beta-4
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Measurements

    Active concentration
    ≈ 50 nM
    actin-binding motif

    Source sentences

    Summary
    Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta4 and the actin-binding motif of the peptide display near-identical activity at ~50 nM, whereas peptides lacking any portion of the actin motif were inactive.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    Peptides lacking any portion of the actin-binding motif of thymosin beta‑4 were inactive in migration and sprouting assays.

    In plain wordsIn lab tests, pieces of thymosin beta‑4 without the actin-binding part had no activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeActivity of peptides lacking the actin motif
    Study

    humann: not reported in source

    HUVEC migration and chick aortic arch sprouting assays
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta4 and the actin-binding motif of the peptide display near-identical activity at ~50 nM, whereas peptides lacking any portion of the actin motif were inactive.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.